Oncopeptides AB (OSTO:ONCO) Cash Flow from Others : kr29.92 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Cash Flow from Others?

Oncopeptides AB's cash flow from others for the three months ended in Dec. 2023 was kr22.16 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2023 was kr29.92 Mil.

Oncopeptides AB Cash Flow from Others Historical Data

The historical data trend for Oncopeptides AB's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Cash Flow from Others Chart

Oncopeptides AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Others

Get a 7-Day Free Trial

-46.90

138.10

-72.39

20.91

18.88

Oncopeptides AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Others	Get a 7-Day Free Trial															18.27	5.97	6.77	-4.98	22.16

Oncopeptides AB Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr29.92 Mil.

Oncopeptides AB Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB (OSTO:ONCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » Cash Flow from Others

Comparable Companies

Traded in Other Exchanges

0RN4:UK OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.